Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people…

About the Author

has written 39386 stories on this site.

Copyright © 2010 Business and Corporate News.